In 2022, IFPA and IPC announced a new partnership to join their clinical expertise and the patient perspective. Here’s what they hope to achieve together.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
The IPC is a proud supporter of World Psoriasis Day by uniting for action with IFPA to advance care and change the perception of psoriatic disease. Watch the video below to hear IPC’s key opinion leaders from around the world discuss this year’s theme – psoriasis and its impact on mental health.
The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations), and IPC (International Psoriasis Council) delivered by staff based at the University of Manchester. Its goal is to provide the benchmark on the burden of psoriasis in all countries and regions throughout the world using comprehensive epidemiological data to inform research, policy, and healthcare.
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.
IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.
The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.
